Current drug safety最新文献

{"title":"Descriptive Analysis of Adverse Drug Events of Three mTOR Inhibitors Using WHO-VigiAccess.","authors":"Prerna Bhati, Prakash Haloi, Havagiray R Chitme","doi":"10.2174/0115748863459321260316063853","DOIUrl":"https://doi.org/10.2174/0115748863459321260316063853","url":null,"abstract":"<p><strong>Introduction: </strong>The mechanistic target of rapamycin (mTOR) pathway regulates cell growth, metabolism, and survival. Its dysregulation contributes to cancer, autoimmune disorders, neurodegeneration, and aging. While mTOR inhibitors such as Sirolimus, Everolimus, and Temsirolimus are therapeutically valuable, they are linked to significant adverse drug reactions (ADRs).</p><p><strong>Objective: </strong>To investigate adverse events (AEs) and ADRs associated with mTOR inhibitors using the World Health Organization's VigiAccess database.</p><p><strong>Methods: </strong>A retrospective descriptive analysis was conducted using ADRs reports from WHOVigiAccess (2000 onward). Data included patient demographics and geographic distribution. Statistical measures such as odds ratios and relative risks were applied to assess risks.</p><p><strong>Results: </strong>Sirolimus showed a 132% increased risk of gastrointestinal (GI) hemorrhage, alongside oral ulceration, highlighting mucosal toxicity. It was also linked to a 67% higher risk of interstitial lung disease and a 63% increased likelihood of ascites. Temsirolimus was associated with a 40% higher risk of pneumonia and a 36% higher risk of sepsis, reflecting immunosuppressive effects.</p><p><strong>Discussion: </strong>The findings underscore the diverse and serious ADRs of mTOR inhibitors, ranging from gastrointestinal and pulmonary complications to heightened infection risk. These outcomes emphasize the need for careful monitoring and risk-benefit evaluation in clinical use.</p><p><strong>Conclusion: </strong>mTOR inhibitors, while effective, pose substantial risks of ADRs including hemorrhage, lung disease, ascites, and infections. Clinicians should weigh therapeutic benefits against potential harms and adopt vigilant monitoring strategies to optimize patient safety.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tenecteplase for Acute Ischemic Stroke: Improved Handling in Emergency Conditions.","authors":"Antonio Siniscalchi, Luca Gallelli, Sabrina Anticoli, Diana Amantea","doi":"10.2174/0115748863475206260508092323","DOIUrl":"https://doi.org/10.2174/0115748863475206260508092323","url":null,"abstract":"<p><p>Tenecteplase, a genetically modified recombinant tissue plasminogen activator with a long half-life, has recently been proposed as a valid alternative to alteplase for thrombolysis in patients with acute ischemic stroke. According to clinical studies and trials, tenecteplase has several practical advantages over alteplase, including administration by single bolus rather than continuous infusion, shorter treatment duration, and possibly associated with fewer complications. Not only do these features increase the efficiency of emergency department workflow, but they also enable faster reperfusion and more rapid transfer to thrombectomy-capable centers. Although clinical evidence strongly suggests that tenecteplase has greater efficacy and safety, its use may lead to implemented \"bridging therapy\" in terms of rapid administration of a full dose of intravenous fibrinolytics before endovascular thrombectomy, enhanced recanalization rates, and improved efficacy of thrombolytic treatment in ischemic stroke patients.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liraglutide Causing Pancreatitis in an Indian Obese Female: A Case Report and Review of the Literature.","authors":"Jitendra Singh, Anju Dinkar, Rajeev Verma, Munna Lal Patel, Ajay Kumar Patwa, Nitin Bharti","doi":"10.2174/0115748863418018251111133620","DOIUrl":"https://doi.org/10.2174/0115748863418018251111133620","url":null,"abstract":"<p><strong>Introduction: </strong>Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is commonly prescribed for obesity and type 2 diabetes mellitus (T2DM). While its metabolic benefits are well-established, rare cases of acute pancreatitis (AP) have raised concerns about drug safety. Despite regulatory warnings from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), causality remains debated due to confounding factors and limited human data.</p><p><strong>Case presentation: </strong>We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation. She had been using liraglutide 0.6 mg/day for one month for weight management. Laboratory investigations revealed significantly elevated serum amylase and lipase, while abdominal ultrasonography and contrast-enhanced CT scan confirmed acute interstitial edematous pancreatitis. No other common etiologies were identified. Prompt discontinuation of liraglutide and supportive care resulted in full clinical recovery within five days.</p><p><strong>Conclusion: </strong>A systematic literature search yielded 10 relevant case reports encompassing 11 cases of liraglutide-induced acute pancreatitis, with our case bringing the total to 12. These cases showed a slight male predominance and favorable outcomes with conservative treatment. Our report thus highlights the need for clinician vigilance and risk-benefit assessment when prescribing liraglutide, emphasizing early drug cessation upon suspicion of pancreatitis.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Effects of Low-Dose Versus Standard-Dose Cyproheptadine on BMI Increase in Children and Assessment of its Adverse Drug Reactions: A Randomized Clinical Trial.","authors":"Negar Javidmehr, Tina Talakesh, Hadi Raeisi, Hassan Talakesh, Saeid Heidari-Soureshjani","doi":"10.2174/0115748863470780260417103722","DOIUrl":"https://doi.org/10.2174/0115748863470780260417103722","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Childhood underweight and low body mass index are major public health concerns. There is no definitive evidence on the dosage adjustment of Cyproheptadine as an appetite stimulant. This study aimed to evaluate the effect of Cyproheptadine on Body Mass Index (BMI) in underweight children and assess its associated adverse effects.</p><p><strong>Methods: </strong>This randomized double-blinded clinical trial study was conducted on thin children aged 2 to 10 years. The study was conducted on three groups of 92 children receiving low-dose Cyproheptadine, standard-dose Cyproheptadine, or placebo. Children were assessed monthly for 4 months for changes in anthropometric indices and treatment-related side effects. Data were analyzed using SPSS version 23 Results: Mean BMI showed significant between-group differences at three and four months (p = 0.001 and p < 0.001, respectively). Drowsiness occurred significantly more often in the standard- dose group than in the low-dose group at all visits (p < 0.001). No significant differences between groups in terms of irritability (p > 0.05). Mood swings were consistently more frequent in both Cyproheptadine groups than in the placebo group (p = 0.03).</p><p><strong>Discussion: </strong>These results are consistent with prior evidence supporting Cyproheptadine's role in promoting weight gain and add important insight into dose-related safety. However, the short follow-up period limits conclusions about long-term outcomes.</p><p><strong>Conclusions: </strong>Low-dose cyproheptadine is an effective and safer therapeutic option for increasing BMI in children, offering efficacy comparable to the standard dose with fewer adverse effects. These results also highlight the necessity of long-term monitoring to ensure sustained efficacy and safety.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Treatment of Nociceptive Pain in DOAC-treated Patients: Could it be Safe?","authors":"Gianmarco Marcianò, Vincenzo Rania, Cristina Vocca, Caterina Palleria, Luca Gallelli","doi":"10.2174/0115748863455676260331182324","DOIUrl":"https://doi.org/10.2174/0115748863455676260331182324","url":null,"abstract":"<p><p>Direct oral anticoagulants (DOACs) are widely prescribed in patients at risk of thromboembolism. Although they are generally safer than warfarin, DOACs still carry a risk of bleeding and drug-drug interactions (DDIs). Nociceptive pain is common and may frequently occur in patients receiving DOAC therapy. In these cases, the European Society of Cardiology recommends avoiding non-steroidal anti-inflammatory drugs (NSAIDs) and preferring acetaminophen. However, acetaminophen is not effective when an inflammatory component is present. Consequently, non-pharmacological approaches or topical NSAIDs are suggested, while, in selected cases, lower-risk NSAIDs such as ibuprofen may be considered. Available evidence clearly indicates that concomitant treatment with NSAIDs and DOACs is associated with an increased risk of bleeding, although the magnitude of risk appears to differ across compounds. In this narrative review, we summarize the current evidence on bleeding risk associated with NSAID-DOAC coadministration, discuss potential DDIs from a pharmacokinetic perspective, and outline directions for future research.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suspected Cutaneous Adverse Reaction Due to Oral Consumption of Siddha Polyherbo-Mineral Formulation, Gandhaga Rasayanam: A Case Report.","authors":"T Subathra, N Chandan, Manish Barvaliya, P Shanmugapriya, G Senthilvel","doi":"10.2174/0115748863460961260323095447","DOIUrl":"https://doi.org/10.2174/0115748863460961260323095447","url":null,"abstract":"<p><strong>Introduction: </strong>The Siddha formulation Gandhaga Rasayanam (GRM) is a classical polyherbo-mineral medicine containing purified sulphur and other herbal ingredients, including Schedule E(1) drugs. It is traditionally used to manage chronic ailments and dermatological conditions. Limited safety data have been documented for Siddha medicines; this report highlights a suspected adverse cutaneous reaction probably associated with GRM.</p><p><strong>Case summary: </strong>A 36-year-old female treated for residual Padarthamarai (Tinea cruris) developed elevated plaque with ill-defined, diffuse borders over the neck and upper back on Day 3 of therapy with GRM in combination with other Siddha medicines. This lesion was inflamed, warm to the touch, and associated with pruritus, itching, and burning. The lesions subsided markedly upon GRM withdrawal and resolved completely after a short course of levocetirizine. The patient was advised to resume other internal medicines, excluding GRM, the most suspected drug, and no recurrence was observed. This implicates GRM as the probable cause of the adverse reaction.</p><p><strong>Conclusion: </strong>This case highlights the potential for adverse reactions even with traditionally regarded safe Ayush formulations and emphasizes the need for vigilant pharmacovigilance and systematic documentation of adverse events to ensure patient safety.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itraconazole-Induced Motor Sensory Polyneuropathy in a Young Indian Male: An Unusual Case.","authors":"Jitendra Singh, Pooja Chaurasiya, Anju Dinkar, Munna Lal Patel, Ajay Kumar Patwa, Isha Atam","doi":"10.2174/0115748863412255251208093326","DOIUrl":"https://doi.org/10.2174/0115748863412255251208093326","url":null,"abstract":"<p><strong>Introduction: </strong>Itraconazole, a widely prescribed triazole antifungal agent, is generally well tolerated but can rarely cause neurotoxicity. Motor-sensory polyneuropathy secondary to itraconazole use is an exceptionally uncommon and underrecognized adverse effect. Although reversibility has been reported in several cases, delayed diagnosis or continued exposure may result in persistent neurological impairment. This case report aims to highlight a rare but clinically significant adverse effect-motor-sensory polyneuropathy-associated with prolonged itraconazole use in an otherwise healthy young adult.</p><p><strong>Case presentation: </strong>We report the case of a 21-year-old previously healthy Indian male student who developed progressive weakness and sensory disturbances in both lower limbs, more pronounced on the left side, after two months of oral itraconazole therapy for onychomycosis. He presented with intermittent headaches for 20 days and worsening lower limb weakness over five days. Neurological examination revealed decreased power in the lower limbs (3/5 in the right lower limb and 2/5 in the left lower limb) and impaired sensation in all upper and lower limbs. Cerebrospinal fluid analysis and brain MRI were normal. Laboratory investigations excluded metabolic, infectious, and autoimmune causes. Nerve conduction studies confirmed motor-sensory polyneuropathy. Based on the clinical course, temporal association, and exclusion of other causes, itraconazole-induced neuropathy was diagnosed. The drug was discontinued, and supportive physiotherapy was initiated. The patient showed significant improvement during hospitalization and at one-month follow-up (5/5 in the right lower limb and 4+/5 in the left lower limb).</p><p><strong>Conclusion: </strong>This case emphasizes the importance of considering itraconazole-induced neuropathy in patients presenting with new-onset neurological symptoms, particularly when there is a clear history of recent itraconazole use. Early recognition and prompt withdrawal of the drug are crucial to prevent permanent neurological deficits and achieve functional recovery.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro Evaluation of Simvastatin Nanoparticle-Coated Implant Healing Abutments: Cytotoxicity and Antibacterial Properties.","authors":"Ali Torab, Zoleikha Asadi, Mohammad Yousef Memar, Mina Yekani, Amin Rasouli, Simin Sharifi, Solmaz Maleki Dizaj","doi":"10.2174/0115748863451702260226073904","DOIUrl":"https://doi.org/10.2174/0115748863451702260226073904","url":null,"abstract":"<p><strong>Introduction: </strong>Simvastatin is a lipid-lowering drug with pleiotropic effects. Several studies have shown that it may have a protective effect on reducing morbidity and mortality from infections. One of the most devastating complications of orthopedic surgery is ImplantAssociated Infections (IAIs). Recently, newer strategies have been tried to reduce implant-related infections. Nanoparticles with antibacterial properties and coating on the healing implant abutment can improve implant performance. This study aimed to investigate the biocompatibility and antimicrobial effects of healing abutments coated with simvastatin nanoparticles (SIM-NPs).</p><p><strong>Methods: </strong>The MTT assay was used to investigate the biocompatibility, and the time-kill assay was used to assess the antibacterial effect of abutments coated with SIM-NPs.</p><p><strong>Results: </strong>The results showed that SIM-NPs coated on implant healing abutments had no cytotoxic effect. The time-kill assay showed that SIM-NP coating conferred antibacterial activity on implant healing abutments (p<0.05).</p><p><strong>Discussion: </strong>The results emphasize the dual advantage of SIM-NP coatings that combine biocompatibility with antibacterial function. Their non-toxic profile protects surrounding tissues, while their antimicrobial function helps prevent initial bacterial attachment and peri-implant infections.</p><p><strong>Conclusion: </strong>The observaitons of this study suggest that SIM-NP coatings may be a valuable alternative to systemic antibiotic therapy, thereby reducing the possibility of antibiotic resistance and minimizing systemic side effects. However, additional studies in animal and clinical studies should be conducted before consideration for clinical application.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Assessment of Body Composition Changes with Sodium Glucose Transporters 2 (SGLT2) Inhibitors in Type 2 Diabetes Mellitus Using Bioelectrical Impedance Analysis.","authors":"Bharti Bhandari, Preeti Kaliramana, Prerna Agarwal, Aprajita Panwar, Saurabh Srivastava","doi":"10.2174/0115748863428807260115055905","DOIUrl":"https://doi.org/10.2174/0115748863428807260115055905","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 Diabetes Mellitus (T2DM) very often leads to adverse changes in body composition, including increased fat mass and sarcopenic obesity. Sodium-Glucose Co- Transporter 2 inhibitors are effective hypoglycaemic medications that also promote weight loss, but their specific impact on body composition remains unclear, particularly in Indian populations. Hence, this study intended to determine the extent of alterations in body composition parameters in T2DM patients on SGLT 2 inhibitor therapy using Bioelectrical Impedance Analysis (BIA).</p><p><strong>Methods: </strong>This prospective observational study enrolled 60 adults with T2DM initiated on SGLT2 inhibitors along with standard therapy. BIA measurements were taken at baseline, 30 days, and 90 days. Parameters included Body Weight (BW), Body Mass Index (BMI), Skeletal Muscle Mass (SMM), Body Fat Mass (BFM), visceral fat percent, and ECW/TBW. Data from 55 patients were analysed. Descriptive statistics were calculated at baseline, 30 days, and 90 days and expressed as mean ± SD. The data were compared by means of repeated measures ANOVA.</p><p><strong>Results: </strong>No significant changes in body composition were observed at 30 days. After 90 days, a statistically significant (p < 0.05) decrease in BW (73.4 ± 10.1 vs 70.4 ± 7.5), BMI (28.5 ± 3.0 vs 27.4 ± 2.6), BFM (30.7 ± 7.3 vs 28.6 ± 5.7), and visceral fat% (13.8 ± 4.4 vs 12.4 ± 3.0) was observed. SMM and ECW/TBW ratio remained unchanged.</p><p><strong>Discussion: </strong>The results demonstrated no significant change in body composition parameters within the first 30 days of SGLT2 inhibitor therapy. However, by 90 days, there was a significant fall in body composition in terms of body weight, BMI, body fat mass, and visceral fat. No changes were observed in skeletal muscle mass and fluid composition during follow-up. The discrepancy in body composition could be due to variation in the patients' baseline measures and lifestyle habits, including diet and physical activity. Our study was limited by its short duration and use of BIA, which is an easy, non-invasive, and more practical modality, but lacks the precision of imaging modalities like DXA or MRI. Furthermore, muscle function was not assessed, which would provide more clinical relevance in interpreting muscle mass changes.</p><p><strong>Conclusion: </strong>Short-term (90-day) SGLT2 inhibitor therapy, primarily Dapagliflozin in T2DM patients, resulted in statistically substantial reductions in BW, BMI, BFM, and visceral fat percentage, with preservation of SMM and fluid balance. Future studies should target a larger sample size, longer follow-up durations, and include assessment of muscle strength. Additionally, the effect of lifestyle modification along with drugs on body composition can also be investigated.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasal Bleeding as a Potential Side Effect of Omega-3 Fatty Acids: A Case Report.","authors":"Zainab Najim Abdul-Nabi","doi":"10.2174/0115748863448971260303083058","DOIUrl":"https://doi.org/10.2174/0115748863448971260303083058","url":null,"abstract":"<p><strong>Background: </strong>Omega-3 fatty acids (omega-3 FAs) have been studied for the potential treatment of Atopic Dermatitis (AD). Dietary supplementation with omega-3 FAs may help in reducing AD symptoms, including the severity of lesions, inflammation, dryness, and pruritus. Nevertheless, because of their antiplatelet action, more cautious use of these supplements has been recommended in patients who have an invasive procedure or who are receiving antiplatelet or anticoagulant therapy.</p><p><strong>Case presentation: </strong>An 18-year-old male patient with AD self-medicated with 1 gram of overthe-counter omega-3 fatty acid orally once daily for 4 weeks. Over this time, he had ten episodes of epistaxis. Baseline coagulation parameters, such as prothrombin time, activated partial thromboplastin time, and platelet count, were also normal. The patient was not on medications affecting the hemostatic process, nor were there any previous polyps or other structural nasal disorders.</p><p><strong>Conclusions: </strong>The potential of omega-3 FA supplementation to increase risk of bleeding, even at typical doses used in clinical trials, should be considered as demonstrated in this case.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}